Drugs / 4-valent HPV Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04425291 | May 2020 → Sep 2021 | adenocarcinoma in situ, anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia grade 2/3 +2 | Shanghai Bovax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01995721 | Feb 2014 → Feb 2017 | recurrent respiratory papillomatosis | National Institute of Child Health, Hungary | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-valent HPV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04425291 ↗ |
| Modality | Vaccine | “4-valent HPV vaccine administered in months 0., 2., 6.” NCT01995721 ↗ |